Ellex Medical Lasers Limited
(ASX:ELX) has received a Chinese Government regulatory extension for iTrack until May 2022.
The eye disease treatment company says its iTrack device, is the only minimally invasive glaucoma surgery (MIGS) approved device, to treat glaucoma in China.
The sale approval of Ellex Medical Lasers device, Ellex iTrack, was extended until 23 May 2022.
The company says China is a key market for its device and it is working with its distributor doctors to build scale in the country.
Shares in Ellex Medical Lasers
(ASX:ELX) are trading 4 per cent higher to $1.04.
